Skip to main content

Table 5 HbA1c-levels as a function of the duration of diabetes

From: Effects of bezafibrate on lipid and glucose metabolism in dyslipidemic patients with diabetes: the J-BENEFIT study

Medication classification

Duration of diabetes classification

n

Baseline maen ± SD

After administration mean ± SD

Difference mean ± SD

All cases

Total

1464

8.44 ± 1.34

7.76 ± 1.29

-0.68 ± 1.34 §

 
 

< 1 year

70

8.65 ± 1.63

7.04 ± 1.08

-1.60 ± 1.82 §

p = 0.002

 

1-5 years

503

8.38 ± 1.35

7.69 ± 1.38

-0.69 ± 1.50 §

 
 

5-10 years

432

8.37 ± 1.25

7.81 ± 1.22

-0.56 ± 1.02 §

 
 

≥ 10 years

459

8.56 ± 1.36

7.90 ± 1.25

-0.66 ± 1.27 §

 

Diabetes drug use

Subtotal

147

7.81 ± 0.95

7.33 ± 1.05

-0.47 ± 1.00 §

 

Before study: not taken

&

< 1 year

14

7.72 ± 0.89

6.52 ± 0.75

-1.20 ± 1.31 ‡

p = 0.012

During study: not taken

1-5 years

75

7.73 ± 0.78

7.45 ± 1.08

-0.28 ± 0.88 ‡

 
 

5-10 years

38

7.85 ± 1.15

7.38 ± 1.13

-0.47 ± 0.97 ‡

 
 

≥ 10 years

20

8.06 ± 1.16

7.36 ± 0.76

-0.70 ± 1,04 ‡

 
  1. Baseline HBA1c levels for 1464 patients were ≥ 7.0%. P values were determined by ANOVA to assess statistically difference among duration of diabetes-subgroup